AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02437110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
Study NCT02437110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100mg twice daily.
Study NCT02437110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50mg once daily.
Study NCT02437110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25mg once daily.
Study NCT04709887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vascular intervention surgery
Description: Segmented distal angiography under the guidance of digital subtraction angiography (DSA) were perform after local anesthesia. The superficial artery is expanded by a 3-4 mm balloon.
Study NCT02587962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Birinapant intravenous (IV) on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
Study NCT02587962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
Study NCT02601482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CON
Study NCT02601482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW-60
Study NCT01700309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young and Active
Description: The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
Study NCT02172534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide low
Study NCT02172534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide medium
Study NCT01712347 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
Study NCT00080847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00080847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00080847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00080847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT02172534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide high
Study NCT02172534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01037894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
Study NCT01037894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: In-patient physiotherapy, occupational therapy and speech therapy.
Study NCT02956590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin
Description: Statin
Study NCT02956590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01870323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Behavioral Group
Description: Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
Study NCT02601482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW-45
Study NCT04921462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septoplasty surgery
Description: septoplasty procedures were performed by a single surgeon using the same technique among all patients. The procedures were conducted under general anesthesia according to the standard preoperative care used in our institution.
Study NCT01870323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART Informational Group
Description: Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
Study NCT04525885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg twice daily (BID)
Description: Gefapixant 45 mg tablet to be administered orally BID
Study NCT04525885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 15 mg BID
Description: Gefapixant 15 mg tablet to be administered orally BID
Study NCT04525885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered orally BID
Study NCT04525885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg BID
Description: Gefapixant 45 mg tablet to be administered orally BID
Study NCT01054547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
Study NCT01054547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
Study NCT05893953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediately feedback device
Description: Sitting in a standard chair with immediate feedback device
Study NCT05893953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unstable chair
Description: sitting in an unstable chair
Study NCT05893953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard chair
Description: Sitting in a standard chair
Study NCT03853824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Increased postoperative surveillance
Description: Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
Study NCT03853824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual postoperative care
Description: Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
Study NCT00877123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral vitamin D 100,000 IU
Description: Oral vitamin D 100,000 IU once a month for three consecutive months.
Study NCT00877123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar placebo once a month for three consecutive months
Study NCT02634190 — intervention group
Intervention type: OTHER
Intervention: Thinprep® LBC
Description: liquid based cytology
Study NCT02634190 — intervention group
Intervention type: OTHER
Intervention: APTIMA® HPV Assay
Description: in vitro diagnostic test
Study NCT02634190 — intervention group
Intervention type: OTHER
Intervention: HR HC2® HPV DNA
Description: in vitro diagnostic test
Study NCT02634190 — intervention group
Intervention type: OTHER
Intervention: Colposcopy
Description: Colposcopy
Study NCT05504967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oradexon
Description: With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study NCT05504967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oradexon
Description: With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study NCT05504967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study NCT00080847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00080847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT05504967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study NCT05504967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study NCT05504967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.
Study NCT02093052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up
Description: Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
Study NCT02093052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education for Families
Description: Enhance children's cognitive development. In-home intervention with parents and children present.
Study NCT01374100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
Study NCT01374100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise
Description: The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
Study NCT01374100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong Exercise
Description: Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
Study NCT01374100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong Exercise
Description: Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
Study NCT00077467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00077467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00077467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03439683 — intervention group
Intervention type: OTHER
Intervention: Survey about patient-ventilator asynchrony
Description: Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
Study NCT02108678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-ME
Description: 1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
Study NCT02108678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Migraine Education Only
Description: 6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
Study NCT04359381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping application
Description: kinesiotaping was applied once the menstrual pain begins (one day before menstruation) for periods of 4 to 5 days until the pain disappears and then removed it. Kinesiotaping was used for 3 successive menstruations.
Study NCT00206544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 40 mg daily of adjunctive tamoxifen in oral capsule
Study NCT00206544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 20 mg daily of adjunctive progesterone in oral capsule
Study NCT04359381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilate exercises program
Description: Each girl in group (B) was engaged in a supervised pilate exercises program for 30 minutes per session for 3 days/week for 12 weeks except days of menstruation. Participants would be oriented to wear comfortable clothes .
Study NCT02403466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resident Handoff Bundle
Description: 1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
Study NCT02642497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-wound instillation of ketamine
Description: intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
Study NCT02642497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intra-wound instillation of normal saline
Description: intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
Study NCT02642497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic administration of ketamine
Description: intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
Study NCT04669418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RNA expression signature
Description: Whole transcriptome profiling using RNA sequencing
Study NCT01376518 — intervention group
Intervention type: PROCEDURE
Intervention: positive end-expiratory pressure
Description: Elevation of positive end-expiratory failure for recruitment
Study NCT01640574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
Study NCT01640574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
Study NCT01640574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
Study NCT01640574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
Study NCT00395343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg tablet qd for a 24-wk treatment period.
Study NCT00395343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator : placebo (unspecified)
Description: sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
Study NCT04268823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule 300mg
Study NCT04268823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule 300mg
Study NCT00080847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01361347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk
Description: milk for milk allergic children (1:25 dilution, whole milk)
Study NCT01361347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk
Description: milk for milk allergic children (1:25 dilution, whole milk)
Study NCT03649152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propagermanium
Description: Immediate release capsule
Study NCT03649152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study NCT01684462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin 20
Description: Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4\~8h, commencing within 12 hours of stroke onset
Study NCT01684462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % Normal Saline
Description: Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
Study NCT03746691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram HCl
Description: Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
Study NCT01409343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrasGEX™
Description: Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
Study NCT03746691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
Study NCT04258579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT with Technology Augmentation
Description: PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.